Trials / No Longer Available
No Longer AvailableNCT03068650
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Celldex Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | rindopepimut | Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination. |
Timeline
- First posted
- 2017-03-03
- Last updated
- 2017-10-18
Source: ClinicalTrials.gov record NCT03068650. Inclusion in this directory is not an endorsement.